Trials / Unknown
UnknownNCT03907800
Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nab-paclitaxel | 125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles. |
| DRUG | Carboplatin | AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles |
| DRUG | Herceptin | In case of HER2-positive, patients receive Herceptin weekly during all cycles. |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
- First posted
- 2019-04-09
- Last updated
- 2022-10-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03907800. Inclusion in this directory is not an endorsement.